https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-20 / Oncologist 2012;17(10):1256-70
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-20 / Oncologist 2012;17(10):1256-702012-08-20 00:00:002019-02-15 08:39:54NK cells: key to success of DC-based cancer vaccines?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-10 / Korean J. Physiol. Pharmacol. 2012 Aug;16(4):243-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-10 / Korean J. Physiol. Pharmacol. 2012 Aug;16(4):243-72012-08-10 00:00:002019-02-15 08:53:36Morphologic evidence of anti-tumor specificity of T cells activated by denritic cells derived from peripheral blood mononuclear cells of thyroid cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-09 / Int. Immunopharmacol. 2012 Nov;14(3):252-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-09 / Int. Immunopharmacol. 2012 Nov;14(3):252-602012-08-09 00:00:002019-02-15 08:53:37Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-07 / Oncol. Rep. 2012 Oct;28(4):1131-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-07 / Oncol. Rep. 2012 Oct;28(4):1131-82012-08-07 00:00:002019-02-15 08:48:47Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-07-01 / Immunotherapy 2012 Jul;4(7):703-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-07-01 / Immunotherapy 2012 Jul;4(7):703-182012-07-01 00:00:002019-02-15 08:39:54Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-06-28 / Lancet Oncol. 2012 Jul;13(7):e301-10
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-06-28 / Lancet Oncol. 2012 Jul;13(7):e301-102012-06-28 00:00:002012-06-28 00:00:00Immunotherapies for non-small-cell lung cancer and mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-06-04 / J Clin Oncol 30, 2012 (suppl; abstr 2546)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-06-04 / J Clin Oncol 30, 2012 (suppl; abstr 2546)2012-06-04 12:06:592019-07-17 12:07:32Phase I immunotherapy trial using glioblastoma apoptotic body-pulsed dendritic cells.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-06-04 / J Clin Oncol 30, 2012 (suppl; abstr e13059)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-06-04 / J Clin Oncol 30, 2012 (suppl; abstr e13059)2012-06-04 11:46:052019-07-17 11:46:27Autologous dendritic cell vaccine (ADCV) in combination with plasmapheresis (PP) and cyclophosphamide (Cy) in patients with disseminated melanoma: A phase II study.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-06-04 / J Clin Oncol 30, 2012 (suppl; abstr 2506)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-06-04 / J Clin Oncol 30, 2012 (suppl; abstr 2506)2012-06-04 00:00:002021-08-09 07:43:36WT1-targeted dendritic cell vaccination as a postremission treatment to prevent or delay relapse in acute myeloid leukemia.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-06-02 / J Clin Oncol 30, 2012 (suppl; abstr 2084)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-06-02 / J Clin Oncol 30, 2012 (suppl; abstr 2084)2012-06-02 12:04:272019-07-17 12:04:49The final report of a phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with glioblastoma.
